https://www.selleckchem.com/pr....oducts/abc294640.htm
Of 49 patients in this study, 27 were in the FOLFIRINOX regimen group and 22 in the Gemox regimen group. There were no significant differences between groups in baseline characteristics. The DCR was 77.8% in the mFOLFIRINOX group and 63.5% in the Gemox group. The corresponding median PFS was 9.9 months (95% confidence interval [CI], 7.3-12.4) in the mFOLFIRINOX group versus 6.4 months (95% CI,3.6-9.2, p = 0.04 in the Gemox group. The corresponding median OS was 15.7 months (95% CI, 12.5-19. versus 12.0 months (95% CI, 9.3-14.8, p
Suka
Komentar
Membagikan
